BTOG 2024 | Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial

Robert Rintoul, from University of Cambridge & Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK, discusses the results of the Phase III IFCT-0302 clinical trial (NCT00198341), which assessed minimal versus CT-scan-based follow-up. The trial followed 1500 post-surgical patients over a median follow-up period of 8.7 years. Patients were randomized into two arms: one receiving clinic follow-up with chest x-rays, and the other receiving more intensive follow-up including CT scans and bronchoscopies. While there was no statistically significant difference in overall survival (OS) between the arms, the intensive arm showed a trend towards longer survival (10.2 years vs. 8.2 years). However, there were more recurrences and second primaries in the intensive arm. Dr Rintoul emphasizes the need for further studies to determine optimal follow-up strategies and the potential integration of biomarkers into follow-up protocols. This interview took place at the BTOG 2024 congress in Belfast, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.